Organogenesis Holdings (ORGO) Equity Average (2016 - 2026)

Organogenesis Holdings' Equity Average history runs 11 years deep, the most recent figure standing at $272.3 million for Q1 2026.

• In Q1 2026, Equity Average rose 7.69% year-over-year to $272.3 million; the TTM figure through Mar 2026 stood at $272.3 million (up 7.69% YoY), while the FY2025 annual figure was $281.5 million, up 3.96% from the prior year.
• Equity Average was $272.3 million for Q1 2026 at Organogenesis Holdings, down from $277.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $278.3 million in Q1 2024 to a low of $238.1 million in Q2 2025.
• Historically, Equity Average has averaged $262.7 million across 5 years, with a median of $267.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Equity Average surged 63.78% in 2022, then retreated 12.07% in 2025.
• A 5-year view of Equity Average shows it stood at $261.0 million in 2022, then climbed by 6.42% to $277.8 million in 2023, then decreased by 2.54% to $270.7 million in 2024, then increased by 2.55% to $277.6 million in 2025, then retreated by 1.9% to $272.3 million in 2026.
• The last three Equity Average figures came in at $272.3 million (Q1 2026), $277.6 million (Q4 2025), and $244.2 million (Q3 2025), per Business Quant data.